The transforming growth factor (TGF)-b superfamily has been implicated into different physiological and pathological processes in a broad range of cell systems, including fibroblasts, immune, stem, endothelial, mural and tumor cells. With three TGF-b isoforms, three activin isoforms and over 20 bone morphogenic proteins (BMPs), the TGF-b superfamily represents a complex signaling pathway. The TGF-b receptor complex is composed of type I, type II and accessory receptors. There are seven isoforms of type I receptors termed activin receptor-like kinases (ALKs) 1-7. Targeted inactivation of TGF-b signaling components in mice revealed the pathway's crucial role in vascular morphogenesis as animals lacking various TGF-b superfamily members die at mid-gestation during embryogenesis because of defects in vascular development. In humans, dysregulation of the pathway is responsible for a broad range of diseases, including vascular diseases, hereditary cancer syndromes and the autosomal-dominant disorder Hereditary Hemorrhagic Teleangiectasia (also named Rendu-Osler-Weber syndrome). In leukemia, the role of TGF-b has been infrequently studied. It has been reported to either stimulate the growth of leukemic blasts in vitro or to reduce blast cell proliferation, thereby rendering them insensitive to chemotherapy (reviewed in Otten et al. 1 ). In acute myeloid leukemia, bone marrow neoangiogenesis has an important pathogenetic role. Increased microvessel density in bone marrow sections from acute myeloid leukemia (AML) patients compared with those patients with reactive disorders has been found. This increase of endothelial cells is accomplished by enhanced production of angiogenic growth factors. Secondly, hematopoietic and endothelial cells are derived from a common precursor, the hemangioblast. Therefore, many surface antigens are shared between both cell types such as CD34 or receptors for vascular endothelial growth factor (VEGF) (reviewed in Ayala et al.
2 ). Hence, we reasoned that the TGF-b superfamily receptors ALK-1 and ALK-5, which have an important role in endothelial cells (EC) behavior, might be involved in the pathogenesis of AML.
In this study, we therefore analyzed expression and prognostic relevance of endothelium-specific ALK-1, ubiquitously expressed ALK-5 and their ligands TGF-b1, BMP-9 and BMP-10 by quantitative PCR (Light Cycler (Roche, Basel, Switzerland) using the FAST Start DNAMaster Sybr Green Kit (Roche)) in pretherapeutic bone marrow or peripheral blood samples from 93 patients with newly diagnosed AML enrolled into the AustrioGerman AMLSG study group (AMLSG 07-04 study). All patients were treated according to a uniform chemotherapy protocol (for details see http://clinicaltrials.gov/ Identifier: NCT00151242). Comprehensive patient's characteristics are listed in Table 1 .
Expression levels of all analyzed genes were quantified as a ratio to the housekeeping gene GAPDH. With 82% and 88% respectively, expression of ALK-1 and ALK-5 m-RNA was detected in the majority of AML patients. Only 8 and 13% of AML patients expressed the ALK-1-specific ligands BMP-9 and However, no significant correlation between expression of ALK-1 and its ligand BMP-9 or BMP-10 was found. Next, we analyzed the prognostic significance of gene expression levels of the members of the TGF-b pathway. Gene expression variables were categorized into two groups, guided by conditional tree models for overall survival (OS), and investigated in relation to clinical variables sex, age, white blood cell count, karyotype and FLT3 mutation status. Because of the low number of cases with a favorable karyotype, patients were categorized in only two risk groups: favorable (t(8;21), inv(16) and normal karyotype) and unfavorable (trisomy 8, abnormalities of chromosome 5, 7, 11 or complex abnormalities). Owing to the low number of patients expressing BMP-9 and BMP-10 (8 and 13%, respectively), we analyzed the combined effect of any BMP expression.
First, achievement of complete remission was investigated in relation to clinical and gene expression variables. Only karyotype and ALK-5 expression had a significant influence on the complete remission rate, which was 27 vs 63% for high vs low ALK-5 expressors (w 2 P ¼ 0.022) and 75 vs 35% for favorable vs unfavorable cytogenetics (w 2 Po0.001). The influence of the gene expressions on event-free survival, relapse-free survival and OS was investigated in a Cox proportional hazards model adjusted for clinical characteristics implementing a stepwise removal of insignificant (P40.05) terms. Univariate analysis revealed that expression of ALK-1, TGF-b1, BMP, ID-1 and plasminogen activator inhibitor-1 had no significant effect on survival. However, ALK-5 expression had a significant impact on EFS, RFS and OS.
Multivariate analysis included gene expression results of ALK-5, TGF-b1, ID-1 and the baseline variables. During the stepwise procedure of Cox regression, the baseline variables sex, age, white blood cell count and FLT3 mutation status as well as TGFb1 and ID-1 gene expression were eliminated. High ALK-5 expression and unfavorable karyotype remained with a significant negative impact on event-free survival, relapse-free survival and overall survival (Hazard Ratios 3.4 (95% confidence interval (CI) 1.7-6.9), 11.7 (95% CI 3.1-44.7) and 2.8 (95% CI 1.3-6.0) for ALK-5 expression, respectively; Hazard Ratios 3.6 (95% CI 2.1-6.0), 4.6 (95% CI 2.1-10.2) and 2.3 (95% CI 1.2-4.1) for karyotype, respectively; see Kaplan-Meier survival curves for high vs low ALK-5 expression in Figure 1A ). To better characterize the patients groups with high and low ALK-5 expressions, clinical characteristics are given in Table 1 . In addition to the karyotype and achievement of complete remission (P ¼ 0.023 and P ¼ 0.046 by Fisher's test, respectively), a significant difference in white blood cell count was found with higher levels in the low ALK-5 expression group (P ¼ 0.047 by t-test). Remarkably, all patients with high ALK-5 expression levels carried the wild-type FLT3. Therefore, we propose that ALK-5 might have a leukemia-promoting role in those AML patients without mutational activation of the FLT3 pathway.
From the patients of the AML-SG study group, only c-DNA samples were available. Therefore, several AML cell lines and primary blasts from patients with de novo AML (but without clinical data available) were analyzed for expression of receptors ALK-1 and ALK-5 on mRNA and protein level. Endothelial cells served as positive controls. As shown in Figure 1B , endothelial cells expressed ALK-1 and ALK-5 by qualitative PCR analysis. Studying leukemic cell lines, we demonstrated that UKE-1, SKM-1, THP-1, MV4-11, Monomac-1 and Kasumi-1 were positive for ALK-1 mRNA, whereas HL-60 was negative for ALK-1 mRNA. All leukemic cell lines were positive for ALK-5 mRNA with Monomac-1 showing only faint expression ( Figure 1B) .
Fluorescence-activated cell sorting analysis confirmed ALK-1 and ALK-5 protein expressions in ECs and leukemic cell lines ( Figure 1C ). Analyzing primary blasts from AML patients we found ALK-5 protein expression in 8 of 10 analyzed samples (ranging from 8 to 66% ALK-5 positive blasts with a median of 27%), but only modest ALK-1 expression in two patients (2 and 3% ALK-1 positive CD34 þ blasts, respectively; Figure 1D ). Immunocytology of the same samples was in concordance with fluorescence-activated cell sorting data, as 7 of 10 samples analyzed showed ALK-5 expression ranging from 3 to 66% (median 24%), whereas ALK-1 was below 1% in all analyzed patients ( Figure 1E) .
Furthermore, formalin-fixed, paraffin-embedded trephine bone marrow specimens from two arbitrarily selected patients with AML and from two patients with non-leukemic reactive changes were analyzed for ALK-1 and ALK-5 expressions by immunohistochemistry. ECs from AML patients and those with reactive disorders were strongly positive for both receptors. In addition, a fraction of AML blasts stained positively for ALK-1 and ALK-5 in AML bone marrows, whereas normal hematopoietic cells were negative for both TGF-b receptors ( Figure 1F ).
The role of the TGF-b receptors ALK-1 and ALK-5 in ECs has been intensively studied. Increased proliferation and migration were observed on stimulation of the TGF-b/ALK-1 pathway, whereas stimulation of the TGF-b/ALK-5 pathway inhibited EC proliferation and migration. 3 It was proposed that ALK-1 and ALK-5 might balance the activation state of endothelium because of their opposing roles. But more recently published data might change this view on the functions of ALK-1 and ALK-5. David et al. 4 showed that not TGF-b1 but BMP-9 and BMP-10 are likely to be physiological ligands for ALK-1, and that these ligands are potent inhibitors of EC proliferation and migration. Shao et al. 5 demonstrated that ALK-1 and ALK-5 are both essential for the regulation of VEGF, which is believed to be the central growth factor in angiogenesis. Stimulation of TGF-b1/ ALK-5, elevated the mRNA levels of VEGF in bovine aortic ECs, whereas BMP-9/ALK-1 stimulation led to decreased VEGF mRNA levels. Proliferation, migration and tube formation assays were in line with the changes in VEGF expression described above, supporting the data of David and colleagues.
4,5 ALK-5 mediated upregulation of VEGF, as proposed by Shao and colleagues, might contribute to the negative direct impact of ALK-5 expression on clinical outcome of AML patients in our study. As VEGF is a major inducer of angiogenesis and could be shown to be upregulated in AML blasts, our findings demonstrate that ALK-5 might be a promising therapeutic target for AML. 2 In fact, inhibition of ALK-5 in CD34 þ cells isolated from patients with myelodysplastic syndrome led to in vitro enhancement of hematopoiesis, which is important as about one-third of myelodysplastic syndrome patients progress to AML. 6 In addition, ALK-5 is expressed on several solid tumor cell lines, including gastric, prostate cancer and hepatoma; an anti-tumor effect for small molecule ALK-5 inhibitors could be shown for these cell lines in vitro and in vivo in animal models (reviewed in Otten et al.
1 ). A growing body of evidence demonstrates that ALK-1 and ALK-5 are dependent on each other. However, data are rare and show opposite effects regarding the question which receptor is required for optimal action of the other. 3, 5 As ALK-1 expression seems to be restricted to endothelial and tumor cells, blockade of this receptor would probably not affect other cell types and might cause less side-effects than manipulation of ALK-5. Indeed, a human anti-ALK-1 antibody is being tested in a phase-I study in patients with advanced solid tumors (NCT00557856). 
Letters to the Editor
Taken together, we could demonstrate in our exploratory study for the first time that the TGF-b superfamily receptors ALK-1 and ALK-5 are both expressed by the majority of AML patients. In addition, ALK-5 expression has a significant negative impact on complete remission achievement and long-term survival of patients. Therefore, ALK-5 represents a new prognostic marker for AML and the ALK-1/ALK-5 pathway might be a promising new therapeutic target. After validation in an independent patient group, further in vitro and in vivo studies should be aimed at elucidating the interaction of ALK-1 and ALK-5 with regard to the progression of leukemia and the therapeutic potential of ALK-1 and ALK-5 inhibitors.
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a global deficiency of glycosylphospatidyl inositol-anchored proteins (GPI-APs) on the membrane of all cell types derived from the affected stem cell.
1 The corresponding clinical phenotype results from the deficiency of GPI-AP on individual cells, and includes a triad of intravascular hemolytic anemia, propensity for thrombosis and bone marrow failure inherently linked to the properties of the affected stem cell. Although the PNH phenotype is non-malignant, outgrowth of GPI-AP (-) clones is mediated by a selective advantage in the context of a permissive condition, such as autoimmune-mediated bone marrow suppression as seen in aplastic anemia. 2 The GPI-AP (-) phenotype results from mutations of the PIG-A gene, located at Xp22.2, which participates in GPI synthesis. 3 Because the gene is X-linked, a single frame-shift or missense inactivating mutation results in loss of GPI-AP expression on the cell surface and because of the X-chromosome inactivation, the frequency of PNH is similar in men and women.
New cytogenetic technologies, such as single-nucleotide polymorphism array-based karyotyping, show superb resolution allowing for detection of submicroscopic chromosomal defects not seen on metaphase spreads. 4 We have systematically applied this technology to identify clonal aberrations in patients with various forms of bone marrow failure. 5 During this molecular screen, a microdeletion of Xp22.2, encompassing the PIG-A locus, was found in three patients with PNH. We have shown that in addition to PIG-A mutations, PNH results from clonal deletion of chromosomal material, likely leading to the same selective clonal advantage as hypomorphic mutation of the PIG-A gene.
The initial observation was made through analysis of a 51-year-old male whose initial presentation of PNH included a thrombotic event (patient #1). The workup of thrombophilia included testing for PNH using flow cytometry; the patient showed diagnostic GPI-AP (-) granulocytes and mild intravascular hemolysis (Figure 1a, left) . On the basis of these findings a diagnosis of a classic PNH was made. Additional testing showed the presence of a JAK2V617F mutation. Laboratory workup included sequencing of PIG-A mRNA in sorted GPI-deficient and normal granulocytes. However, PNH granulocytes yielded no PIG-A complementary DNA amplification product and quantitative PCR demonstrated a lack of PIG-A amplicons from the GPI-AP (-) granulocytes using the normal cell population as the calibrator (Figure 1a, center) . This peculiar finding led to the review of single-nucleotide polymorphism array karyograms from sorted PNH and normal granulocytes; a microdeletion of the PIG-A locus at Xp22.2 was identified in PNH cells while normal cells had an intact X chromosome, confirming the somatic nature of the microdeletion (Figure 1a, right) . The microdeletion spanned 555 kb from bases 15 189 545 to 15 744 107 and included the genes ASB9, ASB and PIR, as well as PIG-A.
We subsequently studied a cohort of patients positive for a significant PNH clone (420%; N ¼ 31) (Table 1 ) using singlenucleotide polymorphism array karyotyping. We identified two additional patients with deletions of Xp22.2. Analogous to the index patient, in the second case (patient # 21), clinical workup was consistent with a diagnosis of PNH, however, JAK2 testing revealed the presence of a V617F mutation. Because nearly all granulocytes were GPI-AP (-) (Figure 1b, left) , corresponding normal granulocytes could not be isolated in sufficient numbers for analysis and we instead separated unaffected lymphocytes. qPCR for PIG-A mRNA expression in the GPI-AP (-) cells showed a complete lack of expression of PIG-A in PNH granulocytes (Figure 1b, center) . The deletion on Xp22.2 spanned 506 kb from bases 15235264 to 15758377 and included PIG-A, as well the neighboring genes ASB9, ASB1, PIR and BMX (Figure 1b, right) . The third patient (patient #28) was a 27-year-old female with a long-standing diagnosis of hemolytic PNH and an almost complete deficiency of normal granulocytes (Figure 1c, left) . In this patient a somatic deletion of the PIG-A locus included nucleotide sequence 15055660 to 15671999, for a total of 616 kb (Figure 1c, right) . Although phenotypically normal cells showed PIG-A expression, virtually no PIG-A amplification product could be obtained in PNH cells (Figure 1c, center) . As the deletion in this patient was hemizygous, the most likely mechanism leading to loss of PIG-A expression is deletion of the allele on the un-inactivated X chromosome. Sequencing of all exons of the remaining PIG-A allele did not reveal any mutations.
Here, we report for the first time patients with apparent PNH and no PIG-A mutations. Instead, the GPI-AP (-) hematopoietic clone results from a microdeletion of the X chromosome encompassing the PIG-A locus. Our observation suggests that in addition to mutations, PNH can be due to a distinct molecular mechanism, namely a chromosomal aberration involving the PIG-A locus. Although three instances of small intragenic deletions, including two p4 kb and one with undefined breakpoints limited to the PIG-A gene, have been reported previously, 6 ,7 our study describes the first cases of PNH due to a true genomic aberration of Xq22 (B500 kb), spanning a number of genes, including PIG-A. There are important implications of this finding with regard to the biology of the disease, as well as its relationship to clonal malignant disorders of hematopoiesis.
The frequency of PNH in men and women is similar. Because of the localization of PIG-A to the X chromosome, the mechanism of action of the deletion leading to loss of PIG-A expression differs
